Author of

• 15343

  +

  P3.03 - Poster Session/ Treatment of Locoregional Disease – NSCLC (ID 214)

  • Event: WCLC 2015
  • Type: Poster
  • Track: Treatment of Locoregional Disease – NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)

  • 15363

    +

    P3.03-020 - Outcomes of Concurrent Chemoradiotherapy in Elderly Patients with Stage III Non-Small Cell Lung Cancer (ID 2252)

    09:30 - 09:30  |  Author(s): J.W. Park
    • Abstract

    Background:
    The aim of this study was to assess the outcomes of concurrent chemoradiotherapy(CCRT) in elderly patients with stage III non-small cell lung cancer(NSCLC), focusing on the survival outcomes, prognostic factors and toxicities.
    
    Methods:
    From January 2006 to May 2012, 39 elderly patients older than 60 years (median 68 years; range 62~78 years) with stage III NSCLC were enrolled in this study. Radiotherapy (RT) was administered to the primary tumor and regional lymph nodes with concomitant administration of chemotherapy. The total RT dose was 46.8-79 Gy in daily 1.8-2.5 Gy fractions (median 66.6 Gy). Overall survival (OS) and progression free survival (PFS) were estimated with the Kaplan-Meyer method. Prognostic factors (gender, age, smoking, pathology, ECOG performance status, body weight, RT dose and tumor response) were analyzed by the log-rank test and Cox regression model. Acute toxicities were assessed according to Radiation therapy oncology group(RTOG) criteria.
    
    Results:
    The median follow-up period was 18.4 months. The 1, 2 and 3-year overall survival(OS) rates were 61.5%, 41.0% and 30.8%, respectively. The 1, 2 and 3-year progression free survival(PFS) rates were 51.7%, 30.0% and 21.8%, respectively. Multivariable analysis showed that ECOG performance status(p=0.002) and tumor response(p=0.001) significantly influenced OS. The tumor response(p=0.013) was a significant prognostic factor for PFS in multivariable analysis. The grade 3 or higher radiation pneumonitis and esophagitis were developed in 9 (23.1%) and 4 (10.3%) patients. Neutropenia with grade 3 or higher was developed in 8 patients (20.8%).
    
    Conclusion:
    Survival (OS and PFS) of elderly patients with stage III NSCLC treated with CCRT is significantly affected by tumor response. However, the survival outcomes for elderly patients with stage III NSCLC treated with CCRT showed comparable results with previous reports. The CCRT related toxicity such as pneumonitis and neutropenia were relatively higher. These results means that CCRT is effective in increasing survival, however, the careful selection of elderly NSCLC patients for CCRT is also required.